Canbud Distribution Corp. (CSE: CBDX) (FSE: CD0) (“Canbud” or the “Company”) is pleased to announce it has signed a Letter of Intent with Hempsana Inc. (“Hempsana”) to develop and manufacture CBD products for distribution to the medical-patient channel.

The United Nations Commission on Narcotic Drugs (CND) accepted and passed a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs on December 2, 2020.This is a major historic win that is highly anticipated to clear the way for an expansion of cannabis research and medical use.


The Biden Administration as incoming POTUS touted their support for cannabis decriminalization during their election campaign.

Canbud believes that the Democrat control of the Congress coupled with the UN decision, provides potential for explosive growth of medical cannabis demand in the US and globally.

According to Research and Markets, the world’s largest market research store, publication in October 2020, Global CBD Oil & CBD Consumer Health Market 2020, “The global CBD oil and CBD consumer health market size is expected to reach USD 123.2 billion by 2027, expanding at a CAGR of 25.6% over the forecast period.”

Canbud is positioning itself to exploit the growth opportunity in the medical CBD and CBD consumer health/nutraceutical markets with strategic moves to synergize with higher margin distribution channels. Pursuant to the patient distribution network development announced last December 29th, 2020, the Company has entered into a strategic partnership with Hempsana, an innovative Canadian cannabis company specializing in cannabis derivatives with a focus on Extraction & Purification. Hempsana’s Health Canada Licenced EU GMP compliant facility provides them with access to wholesale and retail channels internationally, including the EU, Asia, South America, US, and Canada.

Raj Ravindran, CFO, comments: “This strategic partnership with Hempsana is further evidence of our aggressive approach to create accretive revenue streams. This partnership will expand to create more partnerships with global CBD brands to serve the Canadian market as well as other international jurisdictions.”

“We are excited about this endeavour with Canbud and the synergies between the companies as we move forward. This partnership provides Hempsana a pathway into the medical consumer segment of the cannabis industry; more importantly, medical patients will gain access to high-quality cannabis products from Hempsana. By further diversifying our distribution channels we continue to execute on accelerating revenue growth by monetizing our expertise in the medical cannabis sector,” says Randy Ko, CEO and President of Hempsana.

Options grant

The company has granted 300,000 incentive stock options to a consultant of the corporation. The options have an exercise price of 22 cents and a term of 4 years expiring on January 15, 2025.

About Canbud Distribution Corp.

Canbud Distribution Corp is a science and technology health and wellness company that encompasses plant based, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) verticals.

For further information, please contact:
ir@canbudcorp.com
or
Robert Tjandra, President and COO
Tel: 1 416 847 7312

About Hempsana Inc.

Hempsana Inc. is a Canadian cannabis company specializing in cannabis derivatives focussed on Extraction & Purification, and End-Product Manufacturing. The Company has approval for CBD oil extraction in the EU and has been granted Health Canada’s Standard Processing and Industrial Hemp Licenses. Product and Service Offerings include high-quality cannabis derivatives, and end-product development services for cannabis companies.

For further information, please contact:
Randy Ko, CEO & President: randy@hempsana.ca
Peter Kim, SVP, Corporate Development: peter@hempsana.ca
You can also follow us on Twitter at @HempsanaCBD

Notice Regarding Forward Looking Information

Certain information set forth in this news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Corporation, including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward looking information. The Corporation undertakes no obligation to update forward-looking information except as otherwise may be required by applicable securities law.

NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72304

News Provided by Newsfile via QuoteMedia

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less